Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ROCHE HOLDING LTD.
04:10pROCHE : Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, an..
AQ
01:03pROCHE : Clifton sees increase in its tax base
AQ
09:15aAstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/18ROCHE : Ex-Googlers Strike Startup Gold Again With $1.9 Billion Sale
AQ
02/16ROCHE : Diagnostics recognizes Wisconsin Diagnostic Laboratories as Roche Molecu..
AQ
02/16ROCHE : LGC Maine Standards Announces VALIDATE Procalcitonin Kit for Easier Line..
AQ
02/16ROCHE : Slump ends and city sees tax base increase
AQ
02/16ROCHE : acquiring Flatiron for $1.9B
AQ
02/16ROCHE : Ex-Googlers strike startup gold -- again -- with $1.9 billion sale to dr..
AQ
02/16ROCHE : LGC Maine Standards Announces VALIDATE® Procalcitonin Kit for Easier Lin..
AQ
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to Acquire Healthcare-Software Company Flatiron for $1.9 Billion
DJ
02/15ROCHE : to acquire Flatiron Health to accelerate industry-wide development and d..
PU
02/15Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free S..
AQ
02/15FOUNDATION MEDICINE : Researchers from Foundation Medicine Inc. Describe Finding..
AQ
02/15ROCHE : Medical equipments, pharmaceuticals and personal care products
AQ
02/15ROCHE : Architectural, construction, engineering and inspection services
AQ
02/14ROCHE : Genentech - Phase II Data Support Potential for Novel Anti-VEGF/Anti-Ang..
AQ
02/14ROCHE : FDA grants priority review for Roche’s MabThera/ Rituxan (rituxima..
PU
02/14ROCHE : FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for..
BU
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/13ROCHE : bispecific antibody tops Lucentis in diabetic eye disease
AQ
02/13ROCHE : NICE backtracks to recommend Roche`s Gazyvaro in follicular lymphoma
AQ
02/13CENTRAL NERVOUS SYSTEM DRUGS MARKET : Central Nervous System Drugs Market Overv..
AQ
02/13ORIOLA OYJ : Corporation's Financial Statements Release January-December 2017
AQ
02/12ROCHE : Phase II data support potential for Roche’s novel anti-VEGF/anti-a..
PU
02/12ROCHE : Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 ..
BU
02/11ROCHE : College basketball
AQ
02/10BIOPORTO A/S : and Roche Diagnostics sign a distribution agreement for NGAL
AQ
02/09ROCHE : wins UK watchdog's nod for lymphoma drug after initial snub
RE
02/09ROCHE : Pertuzumab gets NICE approval in advanced breast cancer
AQ
02/09ROCHE : Purchases Shares in Tender Offer for Ignyta, Inc
AQ
02/08ILLUMINA : Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.
AQ
02/08FOUNDATION MEDICINE : and European Organisation for Research and Treatment of Ca..
AQ
02/08CHUGAI PHARMACEUTICAL : Investigators at Chugai Pharmaceutical Zero in on Liver ..
AQ
02/08IGNYTA, INC. (NASDAQ : RXDX) Files An 8-K Termination of a Material Definitive A..
AQ
02/08JOHNSON & JOHNSON : IIT-M plans to forge a pact with US biotech hub
AQ
02/08FOUNDATION MEDICINE : UPMC Researchers on Path to Solving Treatment Resistance i..
AQ
02/08ROCHE : Indian hills swimming applies finishing touch
AQ
02/08ROCHE : Behrend falls in battle for first place By Tom Reisenweber
AQ
02/08ROCHE : La Roche 61 Behrend 56
AQ
02/08ROCHE : purchases shares in tender offer for Ignyta, Inc.
PU
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/07Bristol-Myers - Pivotal Phase 3 CheckMate-227 Study Demonstrates Superior Pro..
AQ
02/07ROCHE : NICE restricts NHS use of Roches IPF drug Esbriet
AQ
02/07ROCHE : Releases Sample Collection Device for HIV Plasma Viral Load Testing
AQ
02/07JOHNSON & JOHNSON : Iit-m plans to forge a pact with us biotech hub
AQ
02/06REMINDER : Invitation to Roche's Virtual Pipeline Event
PU
02/06Opdivo plus Yervoy meets in first-line NSCLC with high tumor mutation burden
AQ
02/06ROCHE : Senior at La Roche Awarded PAVE Student Aid Grant
AQ
02/06ROCHE : Dongguan roche industrial co., ltd offering wide range of furniture and ..
AQ
02/06ROCHE : Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and..
PU
02/06ROCHE : Local pharmacies face flu drug supply gap
AQ
02/05ROCHE : Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezoliz..
BU
02/04ROCHE : College basketball
AQ
02/03ROCHE : Refuse skips
AQ
02/02AstraZeneca flags return to drug growth in 2018, China shines
RE
02/02SMITH & NEPHEW : Appointment of Roland Diggelmann as Non-Executive Director
AQ
02/02ROCHE : NICE backs Roches Perjeta for breast cancer
AQ
02/02ROCHE : s Perjeta approved for routine NHS use
AQ
02/02ROCHE : dumps 4 eye, CNS and cancer meds in Q4 clear-out
AQ
02/02GROWING DEMAND FOR MEDICAL ROBOTICS : Medical Robotics Market Overview & Indust..
AQ
02/01FOUNDATION MEDICINE : Lando & Anastasi, LLP Names New Partner in Life Sciences G..
AQ
02/01THERMO FISHER SCIENTIFIC : New Rheumatoid Arthritis Study Findings Reported from..
AQ
02/01European stocks slide on fresh bond jitters
RE
02/01ROCHE : Product Growth on Track, Biosimilars Erode European Sales -- Earnings Re..
DJ
02/01ROCHE HOLDING LTD. : Roche Holding AG to Host Earnings Call
AC
02/01U.S. tax change to help Roche's 2018 profit growth outpace sales
RE
02/01ROCHE : US helps shore up Swiss drugs maker Roche in 2017
AQ
02/01ROCHE : Correction to Roche Earnings Article
DJ
02/01ROCHE : 2017 Net Profit Decreased Due to Impairments
DJ
02/01ROCHE : reports good results in 2017
PU
02/01AUTOMATIC CELL IMAGING SYSTEM MARKET : Automatic Cell Imaging System Market Over..
AQ
01/31ROCHE : MEDICINE COSTS - State secures deal with Roche for cancer drug
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2018 55 357 M
EBIT 2018 18 835 M
Net income 2018 12 211 M
Debt 2018 4 557 M
Yield 2018 3,92%
P/E ratio 2018 15,62
P/E ratio 2019 15,02
EV / Sales 2018 3,61x
EV / Sales 2019 3,46x
Capitalization 195 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 268  CHF
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.37%210 327
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277